Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 999 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hemolysis Clear all
Withdrawn Phase 2 Interventional

Use of Inhaled Nitric Oxide to Prevent Pulmonary Hypertension Associated to Stored Blood Transfusion

NCT02217683
View directory record Official record
Conditions
Hypertension, Pulmonary, Hemolysis
Interventions
Nitric Oxide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2016 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Phase 2 Interventional

A Study of HQK-1001 in Patients With Sickle Cell Disease

NCT01322269
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin S Disease, Sickling Disorder Due to Hemoglobin S
Interventions
HQK-1001
Drug
Lead sponsor
HemaQuest Pharmaceuticals Inc.
Industry
Eligibility
12 Years to 60 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
9
States / cities
Oakland, California • Miami, Florida • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 23, 2026, 6:14 AM EDT
Terminated Phase 3 Interventional Results available

Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease

NCT00530270
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Sacramento, California • Louisville, Kentucky • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 23, 2026, 6:14 AM EDT
Enrolling by invitation No phase listed Observational

Decision-Making and Quality of Life Surrounding Hematologic Disease and Gene Therapy

NCT06664541
View directory record Official record
Conditions
Transfusion Dependent Beta Thalassemia, Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 23, 2026, 6:14 AM EDT
Completed No phase listed Observational

Bone Marrow for Hemoglobinopathy Research

NCT00669305
View directory record Official record
Conditions
Sickle Cell Anemia, Thalassemia
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 23, 2026, 6:14 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

NCT06612268
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Etavopivat, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 23, 2026, 6:14 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)

NCT04853576
View directory record Official record
Conditions
Sickle Cell Disease, Hemoglobinopathies
Interventions
EDIT-301
Genetic
Lead sponsor
Editas Medicine, Inc.
Industry
Eligibility
12 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
21
States / cities
Oakland, California • Aurora, Colorado • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 23, 2026, 6:14 AM EDT
Active, not recruiting Phase 3 Interventional

Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)

NCT04084080
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Red Blood Cell, Standard of care
Biological · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
20
States / cities
Tuscaloosa, Alabama • Oakland, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 23, 2026, 6:14 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

NCT05431088
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Osivelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
46
States / cities
Mobile, Alabama • Hartford, Connecticut • New Haven, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Prasugrel Versus Placebo in Adult Sickle Cell Disease

NCT01167023
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Prasugrel, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Not applicable Interventional Results available

Using Patient-Centered Guidelines in a Technology Platform to Improve Health Care in Adults With Sickle Cell Disease

NCT03629678
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
mobile health application
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

NCT03548220
View directory record Official record
Conditions
Pyruvate Kinase Deficiency, Anemia, Hemolytic
Interventions
Placebo, AG-348
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Little Rock, Arkansas • Atlanta, Georgia • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 23, 2026, 6:14 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

NCT05031780
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Mitapivat, Mitapivat-matching placebo
Drug · Other
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
16 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
28
States / cities
La Jolla, California • Los Angeles, California • Oakland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 23, 2026, 6:14 AM EDT
Not listed Phase 1 Interventional

Dose-Escalation Study of SCD-101 in Sickle Cell Disease

NCT02380079
View directory record Official record
Conditions
Sickle Cell Disease, Sickle-Beta Zero Thalassemia
Interventions
SCD-101
Drug
Lead sponsor
Invenux, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 23, 2026, 6:14 AM EDT
Recruiting Phase 4 Interventional

Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease

NCT06665997
View directory record Official record
Conditions
Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease
Interventions
Depot medroxyprogesterone acetate (DMPA)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

NCT03559699
View directory record Official record
Conditions
Pyruvate Kinase Deficiency, Anemia, Hemolytic
Interventions
AG-348
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Oakland, California • Atlanta, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 23, 2026, 6:14 AM EDT
Terminated Phase 1 Interventional

Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT01335165
View directory record Official record
Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
ALXN1102, ALXN1103
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 23, 2026, 6:14 AM EDT
Terminated No phase listed Observational

Kidney Transplantation in Patients With Sickle Cell Disease

NCT00663507
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Oct 23, 2026, 6:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hydoxyurea Exposure in Lactation A Pharmacokinetics Study (HELPS)

NCT02990598
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Oct 23, 2026, 6:14 AM EDT
Active, not recruiting Phase 2 Interventional

Reduced Intensity Transplantation for Severe Sickle Cell Disease

NCT04362293
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus, hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 25 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Phase 4 Interventional Results available

Actigraphy Improvement With Voxelotor (ActIVe) Study

NCT04400487
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
Voxelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Farmington, Connecticut • Atlanta, Georgia • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 23, 2026, 6:14 AM EDT
Completed Phase 2 Interventional

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

NCT00236041
View directory record Official record
Conditions
Cancer, Breakthrough Pain
Interventions
ACTIQ®
Drug
Lead sponsor
Cephalon
Industry
Eligibility
3 Years to 15 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
30
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 23, 2026, 6:14 AM EDT
Recruiting Not applicable Interventional

Assessing Molecular Mechanisms and Effects of Music Therapy in Youth With Sickle Cell Disease Using Single-cell RNA-sequencing

NCT07562451
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Music Therapy, Standard of Care
Other
Lead sponsor
Emory University
Other
Eligibility
8 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 23, 2026, 6:14 AM EDT
Withdrawn Phase 2 Interventional

Effects of Nitric Oxide on the Endothelium During Hemolysis.

NCT03748082
View directory record Official record
Conditions
Endothelial Dysfunction, Hemolysis Intravascular, Cardiovascular Diseases, Cardiovascular Risk Factor
Interventions
Nitric Oxide, Reactive Hyperemia Index, Endothelial Cells Collection
Drug · Diagnostic Test · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 23, 2026, 6:14 AM EDT